Presentation Information

Free Paper

 

[FP-SA-53] Diabetic Retinopathy
Go back
Day
Apr 05 (Sat)
Time
15:30 - 17:00
Room
Room 23 - Imperial Hotel 3F Fuji
Topic
Retina - Medical
Chair/Coordinator
Chair)Ian Pearce、Chair)Masahito Ohji
 
 
print

FP-SA-53-4

Duration 5min, Q&A 3min

Effects of Intravitreal Ranibizumab on Retinal Hard Exudates in Patients from the RIDE & RISE Diabetic Macular Edema Trials

【Speaker】
Michael Ip
【Author】
Michael Ip Amitha Domalpally Jason Ehrlich


Objective/Purpose
Hard exudates (HE) represent lipid-rich extravascular deposits in the retina that are frequently seen with diabetic macular edema (DME). The presence and growth of HE, particularly near the fovea, is thought to be associated with an increased risk of visual impairment. We analyzed the effect of anti-VEGF therapy with ranibizumab on HE lesions in participants from the RIDE and RISE Phase III trials.

Materials/Patients
Individuals ≧18 years with decreased vision due to DME (study eye best-corrected visual acuity of 20/40 to 20/320 approximate Snellen equivalent) and central subfield thickness of ≧275 μm on time-domain optical coherence tomography.

Methods
A total of 759 patients with DME were randomized 1:1:1 to receive monthly 0.3 mg or 0.5 mg ranibizumab, or sham injections. All groups could receive macular laser therapy from month 3 of study onward, based on predefined criteria. Fundus photographs were graded by a central reading center. The total area of HE in the central, inner and outer subfields of the study eye was categorized as absent (absent or questionable) and present (definite, obvious, moderate or severe). Non-gradable photographs were excluded as missing. Change in total area of HE from baseline was calculated in mm2.

Results and Conclusion
Data from 739 patients were available for analysis. Through 24 months of treatment the percentages of study eyes in the absent category increased from 20.9% to 36.5% in the sham arm and from 22.1% to 60.7% and 23.6% to 61.2% in the ranibizumab 0.3 and 0.5 mg arms, respectively. The resolution of DME was not paralleled by an increase in HE. Decrease in percentage of study eyes in the HE present category was evident after 6 months in the ranibizumab arms. At baseline, there was no correlation between VA and presence of HE in the central subfield in any treatment arm. Post-baseline, there was no consistent correlation between presence of HE in the central subfield and VA change over time.

In this exploratory analysis, ranibizumab appears to result in a reduction in the distribution of HE in patients with DME. However, baseline VA was not associated with the presence of HE, nor was the therapeutic benefit of ranibizumab on visual acuity clearly associated with the presence or absence of HE in the central subfield. Additionally, contrary to prior expectations, the presence and area of HE did not increase as DME resolved (both in the ranibizumab or sham groups).

[ Keyword ]
ranibizumab / anti-VEGF / diabetic macular edema / hard exudates / RIDE RISE trials

[ Conflict of Interest ]
Yes

[ Conflict of Interest (Potential conflict) ]
M. Ip: Consultant: Eye Technology Ltd, Genentech, Inc., Neurogenetics, Valeant, Regeneron, Thrombogenics, Allergan A. Domalpally: No disclosures J.S. Ehrlich: Employee, Stock/Shareholder, Genentech, Inc.

Go back